| Identification | Back Directory | [Name]
satavaptan | [CAS]
185913-78-4 | [Synonyms]
SR 121463
satavaptan
N-tert-butyl-4-[5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indole]-1'-yl]sulfonyl-3-methoxybenzamide
Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy- | [Molecular Formula]
C33H45N3O8S | [MDL Number]
MFCD05662315 | [MOL File]
185913-78-4.mol | [Molecular Weight]
643.79 |
| Hazard Information | Back Directory | [Uses]
Satavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia[1]. | [Definition]
ChEBI: Satavaptan is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. It has a role as a vasopressin receptor antagonist and an aquaretic. It is a member of morpholines, an aromatic ether, a member of benzamides, a secondary carboxamide, a monomethoxybenzene, a sulfonamide and an oxaspiro compound. | [References]
[1] Hoffert JD, et al., Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct. Am J Physiol Renal Physiol. 2014 Feb 15;306(4):410-21. DOI:10.1152/ajprenal.00497.2013 |
|
|